- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04575610
IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)
Study Overview
Detailed Description
Proposed is a randomized, double-blind, placebo-controlled, parallel group Phase 2 study of the efficacy and safety of PF-06650833, an investigational drug, in hospitalized adult male and female patients with SARS-CoV-2-induced ARDS who need mechanical ventilation.
The primary objective of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19, evidence of increased inflammation, and ARDS requiring mechanical ventilation or extracorporeal membrane oxygenation at time of admission.
The secondary objectives of this study are to evaluate:
- Proportion of patients alive, extubated, and receiving no more that low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 2-point improvement in the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale (1 = non hospitalized, no limitations on activity, and 8 = death) at Days 29 and 61
- Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 1-point improvement in the NIAID ordinal scale (1 = non hospitalized, no limitations on activity, and 8 = death) at Days 29 and 61
Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity (Days 8, 15, 22, 29, and 61). The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows:
- Not hospitalized, no limitations on activities;
- Not hospitalized, limitation on activities and/or requiring home oxygen*
- Hospitalized, not requiring supplemental oxygen* - no longer requires ongoing medical care
- Hospitalized, not requiring supplemental oxygen* - requiring ongoing medical care (COVID-19 related or otherwise)
- Hospitalized, requiring supplemental oxygen*;
- Hospitalized, on non-invasive ventilation (NIV)** or high flow oxygen device;
- Hospitalized, on invasive mechanical ventilation or ECMO;
Death
For patients on chronic home O2 supplementation, supplemental O2 is defined as >= home O2 requirement.
- Use of NIV for chronic conditions [e.g. Obstructive sleep apnea (OSA)] is not applicable
- Mortality rate at Day 61
- Time to a 1-point improvement in the NIAID 8-point ordinal scale of disease severity
- Time to a 2-point improvement in the NIAID 8-point ordinal scale of disease severity
- Change from baseline in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and
- Arterial partial pressure of oxygen (PaO2) / Fractional concentration of inspired oxygen (FiO2) ratio (or P/F ratio)
- Change of the Sequential Organ Failure Assessment (SOFA). The SOFA evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.
- Duration (days) of mechanical ventilation
- Ventilator free days
- Safety as assessed by reporting of adverse events (AEs), changes in clinical laboratory parameters (e.g., haemoglobin (Hb), white blood cell (WBC) count, platelets, hepatic transaminases, bilirubin, serum creatinine)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Adult male and female patients, including women of childbearing potential, at least 18 years of age, inclusive
- Participant (or legally authorized representative) capable of giving signed informed consent
- Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection
- Clinical findings and an imaging study consistent with ARDS;
- PaO2 / FiO2 ratio < 300;
- A requirement for mechanical ventilation ≤ 48 hours prior to enrollment.
Evidence of increased inflammation as assessed by hsCRP > ULN AND at least ONE of the following being > upper limit of normal (as available):
- ferritin
- procalcitonin
- D-dimer
- fibrinogen
- LDH
- PT/PTT
EXCLUSION CRITERIA
- Suspected or known active systemic bacterial, viral (except SARS-CoV2 infection), or fungal infections
- Active herpes zoster infection
- Known active or latent tuberculosis (TB) or history of inadequately treated TB
- Active hepatitis B or hepatitis C
- Known history of human immunodeficiency virus (HIV) infection with a detectable viral load or CD4 count < 500 cells / mm3 (patients for whom documented viral load or CD4 counts are available will be excluded)
- Active hematologic cancer
- Metastatic or intractable cancer
- Pre-existing neurodegenerative disease
- Severe hepatic impairment defined as Child-Pugh Class B or Class C at baseline
- Severe renal impairment with an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2
- Severe anemia (Hb < 8.0 g/dL)
Any of the following abnormal laboratory values:
- absolute lymphocyte count <250 cells/mm3
- absolute neutrophil Count (ANC) <1000 cells/mm3
- Platelet count <50,000 cells/mm3
- ALT or AST > 5X ULN, or other evidence of hepatocellular synthetic dysfunction or total bilirubin > 2X ULN
- Any other medical condition or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Prohibited concomitant therapy (see section 1.12.7.2)
- Pregnancy (a negative urine or serum pregnancy test is required for inclusion)
- Immunocompromised patients, patients with known immunodeficiencies or taking potent immunosuppressive agents (e.g., azathioprine, cyclosporine)
- Anticipated survival < 72 hours as assessed by the Investigator.
- Participation in other clinical trials of investigational treatments for COVID-19
- Known history of nephrolithiasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PF-06650833 + Standard of Care
Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO).
All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
|
Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO).
Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD).
Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal).
No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD.
All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
|
ACTIVE_COMPARATOR: Placebo + Standard of Care
Matching placebo tablets will be administered.
|
Matching placebo tablets will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality at Day 29
Time Frame: Up to 29 days
|
All-cause mortality at Day 29 (end of planned treatment period).
|
Up to 29 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Severity (8 point scale)
Time Frame: 29 days
|
Proportion of patients alive, extubated, and receiving no more than low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 2 point decrease in the NIAID ordinal scale. The NIAID scale is as follows:
|
29 days
|
Disease Severity (8 point scale)
Time Frame: 61 days
|
Proportion of patients alive, extubated, and receiving no more than low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients).
This would correspond to an at least 2 point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 61.
|
61 days
|
Disease Severity (8 point scale)
Time Frame: 29 days
|
Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients).
This would correspond to an at least 1-point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 29.
|
29 days
|
Disease Severity (8 point scale)
Time Frame: 61 days
|
Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients).
This would correspond to an at least 1-point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 61.
|
61 days
|
Disease Severity (8 point scale)
Time Frame: 8 days
|
Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 8.
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
|
8 days
|
Disease Severity (8 point scale)
Time Frame: 15 days
|
Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 15.
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
|
15 days
|
Disease Severity (8 point scale)
Time Frame: 22 days
|
Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 22.
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
|
22 days
|
Disease Severity (8 point scale)
Time Frame: 29 days
|
Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 29.
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
|
29 days
|
Disease Severity (8 point scale)
Time Frame: 61 days
|
Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 61.
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
|
61 days
|
Mortality
Time Frame: 61 days
|
Mortality rate at day 61
|
61 days
|
Disease Severity (8 point scale)
Time Frame: 29 days
|
Time to a 1-point decrease in the NIAID 8-point ordinal scale of disease severity (1 = not hospitalized, no limitations on activities, and 8 = death).
|
29 days
|
Disease Severity (8 point scale)
Time Frame: 29 days
|
Time to a 2-point decrease in the NIAID 8-point ordinal scale of disease severity.
|
29 days
|
Disease Severity (8 point scale)
Time Frame: 3 days
|
Change from baseline in the ordinal scale from Day 1 to Days 3.
|
3 days
|
Disease Severity (8 point scale)
Time Frame: 5 days
|
Change from baseline in the ordinal scale from Day 1 to Days 5.
|
5 days
|
Disease Severity (8 point scale)
Time Frame: 8 days
|
Change from baseline in the ordinal scale from Day 1 to Days 8.
|
8 days
|
Disease Severity (8 point scale)
Time Frame: 11 days
|
Change from baseline in the ordinal scale from Day 1 to Days 11.
|
11 days
|
Disease Severity (8 point scale)
Time Frame: 15 days
|
Change from baseline in the ordinal scale from Day 1 to Days 15.
|
15 days
|
Disease Severity (8 point scale)
Time Frame: 22 days
|
Change from baseline in the ordinal scale from Day 1 to Days 22.
|
22 days
|
Disease Severity (8 point scale)
Time Frame: 29 days
|
Change from baseline in the ordinal scale from Day 1 to Days 29.
|
29 days
|
P/F ratio
Time Frame: Up to 29 days
|
PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)
|
Up to 29 days
|
Change of the SOFA score.
Time Frame: Up to 29 days
|
The SOFA evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.
|
Up to 29 days
|
Duration (days) of mechanical ventilation
Time Frame: Up to 29 days
|
The duration is days spent on mechanical ventilation.
|
Up to 29 days
|
Ventilator free days.
Time Frame: Up to 29 days
|
The number of days hospitalized not on a ventilator.
|
Up to 29 days
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: Up to 29 days
|
Up to 29 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hyung Chun, MD, Yale University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000028042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States